Literature DB >> 15313166

Inhibition of the MEK-1/p42 MAP kinase reduces aryl hydrocarbon receptor-DNA interactions.

Sujin Yim1, Myoungsuk Oh, Su Mi Choi, Hyunsung Park.   

Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces expression of the cytochrome P450 1A1 gene, cyp1a1, by binding to its receptor, aryl hydrocarbon receptor (AhR). TCDD-bound AhR translocates to the nucleus and forms a heterodimer with its partner protein, AhR nuclear translocator (Arnt). The AhR/Arnt heterodimer then binds to the dioxin-response elements (DREs) in the cyp1a1 enhancer and stimulates transcription of cyp1a1. We tested whether kinase pathways are involved in this process by treating Hepa1c1c7 cells with kinase inhibitors. The MEK-1 inhibitor PD98059 reduced TCDD-induced transcription of cyp1a1. TCDD treatment results in phosphorylation of p44/p42 mitogen-activated protein kinase (MAPK), a substrate of MEK-1. Overexpression of dominant negative form of p42 MAPK suppressed TCDD-dependent transcription of a reporter gene controlled by dioxin-response elements (DREs), and pretreatment with PD98059 also blocked this transcription. PD98059 pretreatment also inhibited TCDD-induced DRE binding of the AhR/Arnt heterodimer. Together these results indicate that TCDD activates the MEK-1/p44/p42 MAPK pathway, which in turn activates AhR and so facilitates binding of AhR to the cyp1a1 DRE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313166     DOI: 10.1016/j.bbrc.2004.07.072

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways.

Authors:  Alvaro Puga; Ci Ma; Jennifer L Marlowe
Journal:  Biochem Pharmacol       Date:  2008-09-05       Impact factor: 5.858

2.  Prevention of CCAAT/enhancer-binding protein beta DNA binding by hypoxia during adipogenesis.

Authors:  Young-Kwon Park; Hyunsung Park
Journal:  J Biol Chem       Date:  2009-11-25       Impact factor: 5.157

3.  A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.

Authors:  Gianluca Occhi; Susi Barollo; Daniela Regazzo; Loris Bertazza; Francesca Galuppini; Vincenza Guzzardo; Marie Lise Jaffrain-Rea; Federica Vianello; Denis Ciato; Filippo Ceccato; Sara Watutantrige-Fernando; Andrea Bisognin; Stefania Bortoluzzi; Gianmaria Pennelli; Marco Boscaro; Carla Scaroni; Caterina Mian
Journal:  Oncotarget       Date:  2015-10-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.